- Home
- HUBG vs VRDN Comparison
HUBG vs VRDN Comparison
Compare HUBG & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HUBG | VRDN |
|---|---|---|
| Founded | 1971 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.7B |
| IPO Year | 1996 | 2014 |
Fundamental Metrics
Financial Performance| Metric | HUBG | VRDN |
|---|---|---|
| Price | $34.14 | $28.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | ★ $45.33 | $40.92 |
| AVG Volume (30 Days) | 768.4K | ★ 1.1M |
| Earning Date | 05-07-2026 | 05-25-2026 |
| Dividend Yield | ★ 1.46% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.34 | N/A |
| Revenue | ★ $3,946,390,000.00 | $5,706,000.00 |
| Revenue This Year | N/A | $4.67 |
| Revenue Next Year | $2.77 | $331.57 |
| P/E Ratio | $25.59 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $30.75 | $9.90 |
| 52 Week High | $53.26 | $34.29 |
Technical Indicators
Market Signals| Indicator | HUBG | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 24.71 | 47.30 |
| Support Level | $32.43 | $21.50 |
| Resistance Level | $34.49 | $33.71 |
| Average True Range (ATR) | 1.67 | 1.51 |
| MACD | -0.73 | 0.05 |
| Stochastic Oscillator | 2.56 | 59.26 |
Price Performance
Historical ComparisonAbout HUBG Hub Group Inc.
Hub Group ranks among the largest providers of rail intermodal service. Roughly 60% of consolidated revenue comes from Hub's intermodal and transportation solutions division. ITS includes its flagship intermodal operations, which use the Class I rail carriers for the underlying line-haul movement of containers, as well as its dedicated truckload shipping unit. Hub's logistics segment includes its asset-light truck brokerage operations along with its outsourced transportation management, warehousing and fulfillment, and heavy-goods final mile delivery offerings. Hub often makes tuck-in acquisitions that expand its brokerage, last-mile, and dedicated offerings.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).